Heart failure & cardiomyopathiesSecondary analysis
HFpEF-ABA Score and Finerenone in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction
- Secondary analysis of the FINEARTS-HF randomised trial
- placebo-controlled
Authors' conclusion
Despite a proven diagnosis of HF with mildly reduced ejection fraction/HFpEF, one-third of participants in FINEARTS-HF had an HFpEF-ABA score <75%, yet the therapeutic effect of finerenone was consistent across the range of HFpEF-ABA scores included. Higher HFpEF-ABA scores were associated with a greater risk of HF events.
Study context
- Population
- Patients with heart failure (HF) and LVEF ≥40% in FINEARTS-HF
- Participants
- 5,988 available HFpEF-ABA scores
- Comparison
- Finerenone vs placebo across HFpEF-ABA score categories
- <75%n = 1,940
- 75%-90%n = 1,241
- >90%n = 2,807
Primary result
As reported in the abstract
HFpEF-ABA score distribution and outcomes
Original publication
HFpEF-ABA Score and Finerenone in Patients With Heart Failure and Mildly Reduced or Preserved Ejection Fraction. JACC Heart Fail. Published 27 August 2026. doi:10.1016/j.jchf.2026.103297
Summarised from the published abstract; every number is checked against it